Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Johan Lund has been appointed Chairman of the Board, bringing over 25 years of leadership in drug discovery and development from companies such as AstraZeneca and Pfizer. Karin Rosén also joins the Board, adding more than 20 years of global experience in clinical development and medical affairs from companies including Amgen (Horizon), GSK, Genentech (Roche) and Aimmune (Nestlé).
Johan Dighed, Helen Pettersson, David Kendall and Anthony Ford were re-elected to the Board. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
The company’s Founder and Scientific Advisor Bengt von Mentzer stepped down from the Board as part of the renewal process and will continue to be closely involved in the scientific development of PN6047. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
PharmNovo would like to thank Göran Lerenius, who has served as Chairman of the Board since 2017, for his valuable contributions and leadership during this period.
PharmNovo looks forward to working with the newly elected Board as the company continues its development and preparations for the next phase.
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Johan Lund has been appointed Chairman of the Board, bringing over 25 years of leadership in drug discovery and development from companies such as AstraZeneca and Pfizer. Karin Rosén also joins the Board, adding more than 20 years of global experience in clinical development and medical affairs from companies including Amgen (Horizon), GSK, Genentech (Roche) and Aimmune (Nestlé).
Johan Dighed, Helen Pettersson, David Kendall and Anthony Ford were re-elected to the Board. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
The company’s Founder and Scientific Advisor Bengt von Mentzer stepped down from the Board as part of the renewal process and will continue to be closely involved in the scientific development of PN6047. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
PharmNovo would like to thank Göran Lerenius, who has served as Chairman of the Board since 2017, for his valuable contributions and leadership during this period.
PharmNovo looks forward to working with the newly elected Board as the company continues its development and preparations for the next phase.
Latest news
View all
Endowed Chair awarded
We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.
Read more
CTA approval for PN6047
PharmNovo AB is pleased to announce that the clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been approved in Spain. The full title of the study is: “Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia.”
Read more
Breaking new ground in pain management
Breaking new ground in pain management In the latest episode of BioBizBuzz, PharmNovo CEO Per von Mentzer sits down with host Mike Ward to discuss how we’re tackling one of modern medicine’s most urgent challenges: finding effective, non-addictive treatments for chronic and neuropathic pain. The conversation highlights the development of our lead candidate PN6047, a selective delta-opioid receptor agonist designed to deliver strong pain relief without the addiction risks or sedation associated with traditional opioids. Per shares insights into the scientific rationale, clinical potential, and why neuropathic pain—often caused by nerve damage from conditions like diabetes or chemotherapy—demands new thinking. For anyone interested in neuroscience, biotech innovation, or the future of pain management, this episode offers a glimpse into what could become a paradigm shift in treatment. Listen to the full episode here:
Read more
CTA submission for PN6047
PharmNovo AB is pleased to announce that the clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been submitted in Spain. The full title of the application is: “Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia.” Based on a strategic company decision, PharmNovo has submitted the CTA, in the first instance, to the Spanish Health Authorities only. Submission to the Czech Republic and Poland, the two other countries in which the trial will be conducted, is planned to take place following approval in Spain, which is expected by October 2025. Subject to additional investment, patient enrolment is expected to start by Quarter 1 2026.
Read more